A5022869144- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Science, Research, and Medicine
- Cancer Research and Treatments
- Genetic factors in colorectal cancer
- Radiation Therapy and Dosimetry
- Neurological diseases and metabolism
- Prion Diseases and Protein Misfolding
- DNA Repair Mechanisms
- Ubiquitin and proteasome pathways
- RNA regulation and disease
- Mitochondrial Function and Pathology
- Genetic Neurodegenerative Diseases
- Hereditary Neurological Disorders
- ATP Synthase and ATPases Research
- Endoplasmic Reticulum Stress and Disease
- Amyotrophic Lateral Sclerosis Research
AstraZeneca (United Kingdom)
2020-2023
National Institute of Neurological Disorders and Stroke
2022
MRC Laboratory of Molecular Biology
2017-2018
Abstract Purpose: Successful implementation of genomic testing in clinical practice is critical for identification men with metastatic castration-resistant prostate cancer (mCRPC) eligible olaparib and future molecularly targeted therapies. Patients Methods: An investigational trial assay, based on the FoundationOneCDx tissue test, was used to prospectively identify patients qualifying homologous recombination repair gene alterations phase III PROfound study. Evaluation next-generation...
Mitochondrial fission is critically important for controlling mitochondrial morphology, function, quality and transport. Drp1 the master regulator driving fission, but exactly how regulated remains unclear. Here, we identified Drosophila Clueless its mammalian orthologue CLUH as key regulators of Drp1. As with loss drp1, depletion clueless or results in elongation, while drp1 overexpression, overexpression leads to fragmentation. Importantly, rescues adult lethality, tissue disintegration...
Abstract Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization screening techniques reduce failure rates; however, a need remains additional methods to detect cancers alterations in homologous recombination repair genes. We evaluated utility plasma-derived circulating DNA (ctDNA) identifying...
Hereditary spastic paraplegias (HSPs; SPG1-76 plus others) are length-dependent disorders affecting long corticospinal axons, and the most common autosomal dominant forms caused by mutations in genes that encode spastin (SPG4), atlastin-1 (SPG3A) REEP1 (SPG31) proteins. These proteins bind one another shape tubular endoplasmic reticulum (ER) network throughout cells. They also involved lipid droplet formation, enlargement, or both cells, though mechanisms remain unclear. Here we have...
26 Background: Not all mCRPC patients have available or sufficient tissue for multigene molecular testing. In the Phase 3 PROfound study, olaparib significantly improved radiographic progression-free survival compared with physician’s choice of abiraterone enzalutamide in men homologous recombination repair (HRR)-gene-mutated (de Bono et al. N Engl J Med 2020). Overall, 31% patients’ samples failed screening during showing need additional testing methods to detect HRR-gene-mutated cancers....
195 Background: The PROfound study (NCT02987543) showed that olaparib provides a statistically significant improvement in radiographic progression-free survival versus physician’s choice of enzalutamide or abiraterone mCRPC patients (pts) with alterations genes direct indirect role the homologous recombination repair (HRR) pathway. This is largest to date central, prospective tumor tissue testing pts mCRPC. Here, we report learnings during study. Methods: An investigational clinical trial...
<div>AbstractPurpose:<p>Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization screening techniques reduce failure rates; however, a need remains additional methods to detect cancers alterations in homologous recombination repair genes. We evaluated utility plasma-derived circulating DNA...
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
<div>AbstractPurpose:<p>Successful implementation of genomic testing in clinical practice is critical for identification men with metastatic castration-resistant prostate cancer (mCRPC) eligible olaparib and future molecularly targeted therapies.</p>Patients Methods:<p>An investigational trial assay, based on the FoundationOneCDx tissue test, was used to prospectively identify patients qualifying homologous recombination repair gene alterations phase III PROfound...
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
<div>AbstractPurpose:<p>Successful implementation of genomic testing in clinical practice is critical for identification men with metastatic castration-resistant prostate cancer (mCRPC) eligible olaparib and future molecularly targeted therapies.</p>Patients Methods:<p>An investigational trial assay, based on the FoundationOneCDx tissue test, was used to prospectively identify patients qualifying homologous recombination repair gene alterations phase III PROfound...
Supplementary Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)